TherapeuticsMD Inc (NASDAQ:TXMD)‘s stock had its “buy” rating reaffirmed by equities research analysts at Deutsche Bank AG in a report issued on Wednesday. They currently have a $10.00 price objective on the stock. Deutsche Bank AG’s price target would suggest a potential upside of 55.76% from the stock’s previous close.
Several other research firms have also recently commented on TXMD. Morgan Stanley began coverage on TherapeuticsMD in a report on Friday, September 8th. They issued an “equal weight” rating and a $6.00 price target for the company. Jefferies Group LLC reaffirmed a “buy” rating and issued a $15.00 price target on shares of TherapeuticsMD in a report on Friday, September 8th. Oppenheimer Holdings, Inc. set a $10.00 price target on TherapeuticsMD and gave the company a “buy” rating in a report on Thursday, August 17th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $20.00 price target on shares of TherapeuticsMD in a report on Monday, August 21st. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $33.00 price target on shares of TherapeuticsMD in a report on Monday, September 4th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. TherapeuticsMD has an average rating of “Buy” and an average price target of $14.88.
TherapeuticsMD (TXMD) opened at 6.4799 on Wednesday. The firm’s market cap is $1.32 billion. The stock has a 50 day moving average price of $5.89 and a 200 day moving average price of $5.58. TherapeuticsMD has a 12 month low of $3.50 and a 12 month high of $8.30.
TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings results on Thursday, August 3rd. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.01. The firm had revenue of $4.25 million during the quarter, compared to analysts’ expectations of $4.91 million. TherapeuticsMD had a negative return on equity of 77.41% and a negative net margin of 462.94%. The company’s revenue for the quarter was down 3.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.11) EPS. On average, equities analysts expect that TherapeuticsMD will post ($0.44) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This article was originally published by Markets Daily and is the sole property of of Markets Daily. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.themarketsdaily.com/2017/09/13/deutsche-bank-ag-reiterates-buy-rating-for-therapeuticsmd-inc-txmd.html.
In related news, Director Tommy G. Thompson acquired 5,000 shares of the stock in a transaction dated Wednesday, August 30th. The shares were bought at an average cost of $5.99 per share, for a total transaction of $29,950.00. Following the purchase, the director now owns 3,555 shares in the company, valued at approximately $21,294.45. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.
Hedge funds have recently added to or reduced their stakes in the company. Managed Account Services Inc. grew its stake in shares of TherapeuticsMD by 5.5% in the 2nd quarter. Managed Account Services Inc. now owns 19,103 shares of the company’s stock valued at $101,000 after purchasing an additional 1,000 shares during the period. Amalgamated Bank grew its stake in shares of TherapeuticsMD by 7.2% in the 2nd quarter. Amalgamated Bank now owns 19,744 shares of the company’s stock valued at $104,000 after purchasing an additional 1,322 shares during the period. Greenwood Capital Associates LLC grew its stake in shares of TherapeuticsMD by 17.5% in the 1st quarter. Greenwood Capital Associates LLC now owns 20,309 shares of the company’s stock valued at $146,000 after purchasing an additional 3,022 shares during the period. Principal Financial Group Inc. grew its stake in shares of TherapeuticsMD by 3.9% in the 2nd quarter. Principal Financial Group Inc. now owns 21,711 shares of the company’s stock valued at $114,000 after purchasing an additional 818 shares during the period. Finally, Traynor Capital Management Inc. grew its stake in shares of TherapeuticsMD by 14.0% in the 2nd quarter. Traynor Capital Management Inc. now owns 22,799 shares of the company’s stock valued at $123,000 after purchasing an additional 2,799 shares during the period.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.